@article {DeanA37, author = {Emma Dean and Richard Berman and Shaun Villa}, title = {P-101 Solstice: sancuso{\textregistered} in supportive and palliative?care; a feasibility study in patients with cancer and refractory nausea and vomiting}, volume = {7}, number = {Suppl 1}, pages = {A37--A38}, year = {2017}, doi = {10.1136/bmjspcare-2017-00133.100}, publisher = {British Medical Journal Publishing Group}, abstract = {Background Nausea and vomiting (N and V) are common, debilitating symptoms in patients with cancer, often precipitating inpatient admission for subcutaneous/intravenous antiemetics and re-hydration. Currently, there are no evidence-based solutions and treatment algorithms differ across clinical practice. Some of these patients will experience difficulty swallowing tablets and/or are unable to keep oral medications down. Treatments for patients with cancer may also reduce the ability of the intestines to absorb medicines within a tablet.SANCUSO{\textregistered} (Granisetron Transdermal System [transdermal skin patch]) is indicated for the prevention of (N and V) in patients receiving moderately and/or highly emetogenic chemotherapy regimens. The SANCUSO{\textregistered} patch delivers consistent, predictable levels of granisetron throughout five days with smoother daily pharmacokinetics compared to daily dosing. The role of Sancuso in patients with cancer and refractory N and V which is unrelated to chemotherapy has not been explored.Methods An open-label, randomised feasibility study comparing Sancuso with {\textquoteleft}physician{\textquoteright}s choice{\textquoteright} of antiemetic in patients with cancer and refractory N and V. A feasibility study is required at this juncture as standard antiemetic treatment in this patient population is undefined, and the therapeutic efficacy of Sancuso requires appraisal before embarking on a larger randomised trial. To assess feasibility, objectives have been categorised into the four domains; (i) Recruitment - assess the number of patients approached, consent rate, number of eligible patients and explore the methods used to identify potential patients (ii) Patients - willingness to participate and acceptability of the intervention (iii) Clinicians{\textquoteright} - ability to recruit, which physician{\textquoteright}s choice is selected, experience including monitoring of prescribing practice in the control arm (iv) Trial procedures - determine the appropriate primary outcome, adherence/compliance ratesImplications We aim to determine whether this approach is feasible and warrants further investigation in a larger randomised Phase II trial leading to a confirmatory multi-centre randomised Phase III trial to include a cost-effectiveness appraisal.}, issn = {2045-435X}, URL = {https://spcare.bmj.com/content/7/Suppl_1/A37.2}, eprint = {https://spcare.bmj.com/content/7/Suppl_1/A37.2.full.pdf}, journal = {BMJ Supportive \& Palliative Care} }